Navigation Links
n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
Date:9/2/2008

1)

* Difference between groups statistically significant (adjusted analysis; adapted from reference 1)

The GISSI group initiated, designed and conducted the GISSI-HF trial following positive results of a post-hoc analysis of the GISSI-Prevenzione trial (see Notes to Editors) which demonstrated that a subgroup of post-myocardial infarction patients with left ventricular dysfunction had reduced all-cause mortality and hospitalisations with n-3 PUFAs (2).

The primary objectives of the GISSI-HF trial were to demonstrate whether n-3 PUFAs or rosuvastatin improved all-cause mortality or hospitalisations for cardiovascular reasons. Participants were first randomised to receive n-3 PUFAs vs placebo (ORT). A subset of study participants was further randomised to receive rosuvastatin vs placebo.

GISSI-HF-the second large-scale cardiovascular outcome trial of n-3 PUFAs-also confirmed and further supports the safety of n-3 PUFAs, whose cardiovascular benefit in post- myocardial infarction patients had been established by the GISSI-Prevenzione trial (3). Accordingly, current indications of n-3 PUFAs are secondary prevention in post-myocardial infarction patients and treatment of hypertriglyceridaemia. Ongoing studies of n-3 PUFAs in other cardiovascular indications may unveil additional benefits in patients with cardiovascular diseases.

Professor Clemens Von Schacky, Head of Preventive Cardiology, University of Munich, Germany, also reviewed the GISSI-HF trial outcomes and presented the implications of these results for clinical practice during a Solvay-sponsored symposium at ESC 2008. He commented. "Very recently, we have seen a number of large outcome trials in congestive heart failure using a variety of approaches. Unfortunately, these were either neutral or negative. In sharp contrast, GISSI-HF, a meticulously conducted trial, reported the safety and efficacy of n-3 PUFAs in this patient population. Thus, evidence has been provided for guid
'/>"/>

SOURCE Solvay Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
2. National Study Shows Magnesium Sulfate Reduces Risk of Cerebral Palsy in Premature Births
3. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
4. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
5. New Study: Pine Bark Significantly Reduces Menstrual Pain
6. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
7. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
8. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
9. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
10. CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
11. Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 BiondVax Pharmaceuticals Ltd. ... analysis of results from a study which demonstrates that BiondVax,s ... trial which took place in 2012, provided participants with increased ... time of the study- in particular the current newly emerged ... the United States in 2015. ...
(Date:8/3/2015)... SAN DIEGO , Aug. 3, 2015  Sorrento ... that it has entered into an exclusive licensing agreement ... or biobetter antibodies from Mabtech Limited, a holding company ... China . Under the ... these 4 monoclonal antibodies (mAbs) for the North American, ...
(Date:7/31/2015)... July 31, 2015  Physicians and payers alone ... biopharmaceutical market. Patients are better informed and getting ... switching therapies. This shift in power is reshaping ... toward patient-focused marketing. As part of ... learned it,s important to educate, communicate and engage ...
Breaking Medicine Technology:Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2
... N.J., July 11, 2011 MonoSol Rx, a ... PharmFilm® technology platform, in collaboration with APR Applied ... that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble ... partners.  The Company made the strategic decision to ...
... YORK, July 11, 2011 Reportlinker.com announces ... available in its catalogue: ... approval brings lessons and hope to market ... To order this report: ...
Cached Medicine Technology:MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 2MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 3
(Date:8/3/2015)... ... August 03, 2015 , ... Representatives with Health ... on its website. , “Our ‘Ask a Nutritionist’ feature on our website is a ... healthily,” said Liza Brisk, nutritionist and spokeswoman for Health Food Grocers. , Health Food ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data ... IT to create efficiencies in healthcare information exchange, announced the release of its findings ... and Human Services (HHS) Secretary, WEDI shared survey results and recommendations ...
(Date:8/3/2015)... ... ... They know every second counts. And when it comes to stroke, the ... best care in the nation. For the past two months, the stroke team led ... time in the country. During the months of June and July, it took the ...
(Date:8/3/2015)... ... 03, 2015 , ... BESLER Consulting today announced the firm ... The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and creative ... of their Readmissions Analytics product was selected as one of four finalists in ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest ... pharmacogenetic lab testing and precision medicine solutions that can help pharmacists and other ... more than 8.6 million adverse drug events are reported in the U.S. ...
Breaking Medicine News(10 mins):Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 2Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3
... threeat to the globe as 95% of the AIDS ... General Assembly Special Session on HIV/AIDS, physicians demanded to ... would cater the AIDS victims in developing countries. ... (commonly known as Medicines Sans Frontieres, or MSF), MSF ...
... herbal product ginseng root has a number of psychological ... boosting mood performance. But researchers have found no psychological ... PhD, associate professor and co-director of the sport and ... Corvallis, Oregon and his colleague, Hermann Engles, PhD, conducted ...
... inherited disease of the nervous system due to the ... such as involuntary movements and balance problems and later ... well. ,All these days, until now, it was ... form of the protein 'huntingtin' which is responsible for ...
... bacteria known as E. coli 0157:H7 causes some of ... adults. Infections with this organism are often caused by ... to treat children with E. coli bacterial infection increases ... ,"Our data suggests that antibiotics are not only ...
... go in for strategic alliances among themselves to ... and precluding cut-throat competition which would be detrimental ... the Commerce Secretary, Mr. Prabir Sengupta, at the ... Pharmaceuticals and Cosmetics Export Promotion Council here on ...
... its true , this salient disclosure revealed its truth when ... Dr. Fernando D. Martinez ,According to Dr.Fernando D.Martinez and collegues ... between 6 and 11 years of age have a sevenfold ... any such associated risk of asthma even if they are ...
Cached Medicine News:Health News:Pharma cos must forge Strategic alliances 2
... 1575 immunowash microplate washer ... needle position to perform ... maximize wash efficiency. This ... choice of wash that ...
... LMW Automated Microplate ... choice for any laboratory. ... sensor allows a precise ... residual volume, digitally controlled ...
... ELx50 is a fast and versatile automated strip ... manifold. It is a self contained and programmable ... fluidic delivery from the gentle dripping of a ... pressure delivery systems. ELx50/12V processes 1 x 12 ...
... The Microplate washer MP-1200 is ... microplate washing system. Its internal micropumps ... and to discharge from all types ... microplate to be washed in rows ...
Medicine Products: